Literature DB >> 21393444

Transcriptional regulation of the human P450 oxidoreductase gene: hormonal regulation and influence of promoter polymorphisms.

Meng Kian Tee1, Ningwu Huang, Izabella Damm, Walter L Miller.   

Abstract

P450 oxidoreductase (POR) is the flavoprotein that acts as the obligatory electron donor to all microsomal P450 enzymes, including those involved in hepatic drug metabolism as well as three steroidogenic P450 enzymes. The untranslated first exon of human POR was located recently, permitting analysis of human POR transcription. Expression of deletional mutants containing up to 3193 bp of the human POR promoter in human adrenal NCI-H295A and liver Hep-G2 cells located the proximal promoter at -325/-1 bp from the untranslated exon. Common human POR polymorphisms at -208 and -173 had little influence on transcription, but the polymorphism at -152 reduced transcription significantly in both cell lines. EMSA and supershift assays identified binding of Smad3/Smad4 between -249 and -261 and binding of thyroid hormone receptor-β (TRβ) at -240/-245. Chromatin immunoprecipitation showed that Smad3, Smad4, TRα, TRβ, and estrogen receptor-α were bound between -374 and -149. Cotransfection of vectors for these transcription factors and POR promoter-reporter constructs into both cell types followed by hormonal treatment showed that T(3) exerts major tropic effects via TRβ, with TRα, estrogen receptor-α, Smad3, and Smad4 exerting lesser, modulatory effects. T(3) also increased POR mRNA in both cell lines. Thyroid hormone also is essential for rat liver POR expression but acts via different transcription factor complexes. These are the first data on human POR gene transcription, establishing roles for TRβ and Smad3/4 in its expression and indicating that the common polymorphism at -152 may play a role in genetic variation in steroid biosynthesis and drug metabolism.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21393444      PMCID: PMC3082333          DOI: 10.1210/me.2010-0236

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  62 in total

1.  Transcriptional induction of hepatic NADPH: cytochrome P450 oxidoreductase by thyroid hormone.

Authors:  H C Li; D Liu; D J Waxman
Journal:  Mol Pharmacol       Date:  2001-05       Impact factor: 4.436

2.  Regulation by adrenocorticotropin (ACTH), angiotensin II, transforming growth factor-beta, and insulin-like growth factor I of bovine adrenal cell steroidogenic capacity and expression of ACTH receptor, steroidogenic acute regulatory protein, cytochrome P450c17, and 3beta-hydroxysteroid dehydrogenase.

Authors:  C Le Roy; J Y Li; D M Stocco; D Langlois; J M Saez
Journal:  Endocrinology       Date:  2000-05       Impact factor: 4.736

3.  Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis.

Authors:  Ningwu Huang; Amit V Pandey; Vishal Agrawal; William Reardon; Pablo D Lapunzina; David Mowat; Ethylin Wang Jabs; Guy Van Vliet; Joseph Sack; Christa E Flück; Walter L Miller
Journal:  Am J Hum Genet       Date:  2005-03-25       Impact factor: 11.025

4.  Differential interaction of estrogen receptor and thyroid hormone receptor isoforms on the rat oxytocin receptor promoter leads to differences in transcriptional regulation.

Authors:  N Vasudevan; G Davidkova; Y S Zhu; N Koibuchi; W W Chin; D Pfaff
Journal:  Neuroendocrinology       Date:  2001-11       Impact factor: 4.914

5.  Regulation of hepatic cytochrome P450 2C11 via cAMP: implications for down-regulation in diabetes, fasting, and inflammation.

Authors:  H Iber; T Li-Masters; Q Chen; S Yu; E T Morgan
Journal:  J Pharmacol Exp Ther       Date:  2001-04       Impact factor: 4.030

6.  Evaluation of regulatory potential and conservation scores for detecting cis-regulatory modules in aligned mammalian genome sequences.

Authors:  David C King; James Taylor; Laura Elnitski; Francesca Chiaromonte; Webb Miller; Ross C Hardison
Journal:  Genome Res       Date:  2005-07-15       Impact factor: 9.043

7.  Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and/or impaired steroidogenesis: molecular and clinical studies in 10 patients.

Authors:  Maki Fukami; Reiko Horikawa; Toshiro Nagai; Toshiaki Tanaka; Yasuhiro Naiki; Naoko Sato; Torayuki Okuyama; Hideo Nakai; Shun Soneda; Katsuhiko Tachibana; Nobutake Matsuo; Seiji Sato; Keiko Homma; Gen Nishimura; Tomonobu Hasegawa; Tsutomu Ogata
Journal:  J Clin Endocrinol Metab       Date:  2004-10-13       Impact factor: 5.958

Review 8.  Mechanism of thyroid hormone action.

Authors:  Clare B Harvey; Graham R Williams
Journal:  Thyroid       Date:  2002-06       Impact factor: 6.568

9.  Retinoic acid receptors interfere with the TGF-beta/Smad signaling pathway in a ligand-specific manner.

Authors:  Valérie Pendaries; Franck Verrecchia; Serge Michel; Alain Mauviel
Journal:  Oncogene       Date:  2003-11-06       Impact factor: 9.867

10.  Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1.

Authors:  Eleni Aklillu; Juan Antonio Carrillo; Eyasu Makonnen; Karin Hellman; Marià Pitarque; Leif Bertilsson; Magnus Ingelman-Sundberg
Journal:  Mol Pharmacol       Date:  2003-09       Impact factor: 4.436

View more
  12 in total

1.  Consequences of POR mutations and polymorphisms.

Authors:  Walter L Miller; Vishal Agrawal; Duanpen Sandee; Meng Kian Tee; Ningwu Huang; Ji Ha Choi; Kari Morrissey; Kathleen M Giacomini
Journal:  Mol Cell Endocrinol       Date:  2010-11-09       Impact factor: 4.102

2.  The P450 oxidoreductase (POR) rs2868177 and cytochrome P450 (CYP) 2B6*6 polymorphisms contribute to the interindividual variability in human CYP2B6 activity.

Authors:  Li-Chen Gao; Fang-Qun Liu; Li Yang; Lin Cheng; Hai-Ying Dai; Ran Tao; Shi-Peng Cao; Di Wang; Jie Tang
Journal:  Eur J Clin Pharmacol       Date:  2016-07-20       Impact factor: 2.953

3.  Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose.

Authors:  Xiuling Zhang; Lei Li; Xinxin Ding; Laurence S Kaminsky
Journal:  Drug Metab Dispos       Date:  2011-05-11       Impact factor: 3.922

4.  Identification of six novel P450 oxidoreductase missense variants in Ashkenazi and Moroccan Jewish populations.

Authors:  Mária Tomková; Christopher C Marohnic; David Gurwitz; Ondřej Seda; Bettie Sue Siler Masters; Pavel Martásek
Journal:  Pharmacogenomics       Date:  2012-04       Impact factor: 2.533

5.  Nicotine induced CpG methylation of Pax6 binding motif in StAR promoter reduces the gene expression and cortisol production.

Authors:  Tingting Wang; Man Chen; Lian Liu; Huaiyan Cheng; You-E Yan; Ying-Hong Feng; Hui Wang
Journal:  Toxicol Appl Pharmacol       Date:  2011-09-24       Impact factor: 4.219

Review 6.  NADPH-cytochrome P450 oxidoreductase: prototypic member of the diflavin reductase family.

Authors:  Takashi Iyanagi; Chuanwu Xia; Jung-Ja P Kim
Journal:  Arch Biochem Biophys       Date:  2012-09-11       Impact factor: 4.013

7.  Cytochrome P450 oxidoreductase genetic polymorphisms A503V and rs2868177 do not significantly affect warfarin stable dosage in Han-Chinese patients with mechanical heart valve replacement.

Authors:  Sheng-Lan Tan; Zhi Li; Wei Zhang; Guo-Bao Song; Li-Ming Liu; Juan Peng; Zhao-Qian Liu; Lan Fan; Xiang-Guang Meng; Lian-Sheng Wang; Yao Chen; Xin-Min Zhou; Hong-Hao Zhou
Journal:  Eur J Clin Pharmacol       Date:  2013-08-16       Impact factor: 2.953

8.  CyTRANSFINDER: a Cytoscape 3.3 plugin for three-component (TF, gene, miRNA) signal transduction pathway construction.

Authors:  Gianfranco Politano; Francesca Orso; Monica Raimo; Alfredo Benso; Alessandro Savino; Daniela Taverna; Stefano Di Carlo
Journal:  BMC Bioinformatics       Date:  2016-04-08       Impact factor: 3.169

Review 9.  Crosstalk of HNF4α with extracellular and intracellular signaling pathways in the regulation of hepatic metabolism of drugs and lipids.

Authors:  Hong Lu
Journal:  Acta Pharm Sin B       Date:  2016-07-28       Impact factor: 11.413

10.  Intensification of doxorubicin-related oxidative stress in the heart by hypothyroidism is not related to the expression of cytochrome P450 NADPH-reductase and inducible nitric oxide synthase, as well as activity of xanthine oxidase.

Authors:  Jaroslaw Dudka; Franciszek Burdan; Agnieszka Korga; Magdalena Iwan; Barbara Madej-Czerwonka; Monika Cendrowska-Pinkosz; Agnieszka Korobowicz-Markiewicz; Barbara Jodlowska-Jedrych; Wlodzimierz Matysiak
Journal:  Oxid Med Cell Longev       Date:  2012-08-23       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.